sellWeak cluster of 210b5-1 plan
Cedric Francois sold $2.8M of APLS
Chief Executive Officer at Apellis Pharmaceuticals, Inc.. 139,365 shares at an average of $20.19, traded Jul 14, 2025, filed Jul 16, 2025.
Warning score
33Value
$2.8M
139,365 shares
Holdings after
342,333
-29% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$2.8M at market
- +10Share of holdings soldSold 29% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001127602-25-019265, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 14, 2025 | MOption exercise Common Stock10b5-1 | +65,203 | $4.31 | $281k | 480,898 | Jul 16, 2025 |
| Jul 14, 2025 | SOpen-market sale Common Stock10b5-1 | -137,465 | $20.19 | $2.8M | 343,433 | Jul 16, 2025 |
| Jul 15, 2025 | MOption exercise Common Stock10b5-1 | +800 | $4.31 | $3,448 | 344,233 | Jul 16, 2025 |
| Jul 15, 2025 | SOpen-market sale Common Stock10b5-1 | -1,900 | $20.09 | $38k | 342,333 | Jul 16, 2025 |
| Jul 14, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -65,203 | $0.00 | $0 | 110,335 | Jul 16, 2025 |
| Jul 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -800 | $0.00 | $0 | 109,535 | Jul 16, 2025 |
Related signals
Other insiders at Apellis Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | APLSsell Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $8,153 368 shares | -0% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $170k 7,832 shares | -8% | |
| 49Moderate | Apellis Pharmaceuticals, Inc. | Timothy Eugene Sullivan Chief Financial Officer | $224k 10,287 shares | -10% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Nur Nicholson Chief Technical Officer | $168k 7,725 shares | -10% | |
| 59Moderate | Apellis Pharmaceuticals, Inc. | Cedric Francois Chief Executive Officer | $592k 27,192 shares | -9% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Pascal Deschatelets Chief Scientific Officer | $129k 5,928 shares | -1% | |
| 38Weak | Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $73k 3,371 shares | -4% | |
| 36Weak | Apellis Pharmaceuticals, Inc. | James George Chopas VP/Chief Accounting Officer | $45k 2,064 shares | -4% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | Caroline Baumal Chief Medical Officer | $61k 2,797 shares | -3% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $49k 2,475 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.